On Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) was 4.17% up from the session before settling in for the closing price of $35.29. A 52-week range for IONS has been $23.95 – $52.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -8.88% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -4.64%. With a float of $155.28 million, this company’s outstanding shares have now reached $159.04 million.
In an organization with 1069 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.75%, operating margin of -65.85%, and the pretax margin is -64.7%.
Ionis Pharmaceuticals Inc (IONS) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Ionis Pharmaceuticals Inc stocks. The insider ownership of Ionis Pharmaceuticals Inc is 2.44%, while institutional ownership is 104.26%. The most recent insider transaction that took place on May 01 ’25, was worth 477,900. In this transaction Director of this company bought 15,000 shares at a rate of $31.86, taking the stock ownership to the 50,219 shares. Before that another transaction happened on Apr 16 ’25, when Company’s EVP, Corp and Development Ops sold 680 for $28.37, making the entire transaction worth $19,292. This insider now owns 56,660 shares in total.
Ionis Pharmaceuticals Inc (IONS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -4.64% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
You can see what Ionis Pharmaceuticals Inc (IONS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 9.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.98, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -3.13 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.35 million. That was inferior than the volume of 1.66 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 88.46%. Additionally, its Average True Range was 1.19.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 98.54%, which indicates a significant increase from 96.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.64% in the past 14 days, which was lower than the 46.17% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.28, while its 200-day Moving Average is $35.53. However, in the short run, Ionis Pharmaceuticals Inc’s stock first resistance to watch stands at $37.31. Second resistance stands at $37.86. The third major resistance level sits at $38.77. If the price goes on to break the first support level at $35.85, it is likely to go to the next support level at $34.94. Assuming the price breaks the second support level, the third support level stands at $34.39.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
There are 159,159K outstanding shares of the company, which has a market capitalization of 5.85 billion. As of now, sales total 705,140 K while income totals -453,900 K. Its latest quarter income was 131,610 K while its last quarter net income were -146,940 K.
